In a significant showcase for investors, BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will announce major advancements to its industry-leading oncology ...

Neoadjuvant cobolimab and dostarlimab followed by surgery and adjuvant dostarlimab may confer benefits over perioperative pembrolizumab in patients with high-risk, resectable melanoma.

The firm hopes to overcome common dose-limiting toxicities with its PSMA-targeted radiotherapy while boosting potency versus competitors.

The SEQUOIA arm D study demonstrates promising outcomes for treatment-naive patients with CLL, including high-risk patients.

Defect-free quadruple medication therapy significantly improved at discharge, 30 days in patients with heart failure with reduced ejection fraction.

New findings reveal mirvetuximab soravtansine significantly improves outcomes in patients with recurrent platinum-sensitive ...

Shares of Exelixis, Inc. EXEL gained 7.4% on June 23, after the company announced positive top-line results from the ...

ATX-559, a first-in-class oral DHX9 inhibitor, shown to induce potent and selective tumor growth inhibition in preclinical models of cancers with high genomic instability and replication stress ...

Nimbus Therapeutics Announces Initiation of First-in-Human Clinical Trial with NDI-219216, Novel WRN Inhibitor for MSI-H Tumors. ... (AACR) Annual Meeting being held April 25-30, 2025 in Chicago.

Americans are being killed by drugs laced with fentanyl. But the good news is, naloxone, which can reverse fentanyl’s deathly effect, is now available for free in Georgia.

In patients with heart failure, SGLT2 inhibitors after TAVI are associated with major risk reductions in a clinical trial that multiple experts are calling practice changing.

AstraZeneca’s attempt to get an oral option to patients in the form of AZD0780 remains behind Merck & Co.’s own oral PCSK9 inhibitor MK-0616, which is already undergoing a slate of phase 3 ...